Ogeda S.A.

Also on record

Records under this name other than the patents Ogeda S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 19 patents it holds.

Back to Ogeda S.A.

Patent	Title	Status	Expires	Confidence
US 10,017,468	Substituted pyrrolidines as G-protein coupled receptor 43 agonists Formerly held In force Term ends Dec 17, 2030 · From the USPTO record	In force	Term ends Dec 17, 2030	From the USPTO record
US 10,358,416	Substituted pyrrolidines as G-protein coupled receptor 43 agonists Formerly held In force Term ends Dec 17, 2030 · From the USPTO record	In force	Term ends Dec 17, 2030	From the USPTO record
US 9,695,120	Substituted pyrrolidines as G-protein coupled receptor 43 agonists Formerly held In force Term ends Jun 3, 2032 · From the USPTO record	In force	Term ends Jun 3, 2032	From the USPTO record
US 9,987,274	N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Formerly held In force Ends no later than Mar 28, 2034 · From the USPTO record	In force	Ends no later than Mar 28, 2034	From the USPTO record
US 10,030,025	Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Formerly held In force Ends no later than Mar 28, 2034 · From the USPTO record	In force	Ends no later than Mar 28, 2034	From the USPTO record
US 10,183,948	N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Formerly held In force Ends no later than Mar 28, 2034 · From the USPTO record	In force	Ends no later than Mar 28, 2034	From the USPTO record
US 10,836,768	N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Formerly held In force Ends no later than Mar 28, 2034 · From the USPTO record	In force	Ends no later than Mar 28, 2034	From the USPTO record
US 9,770,435	Compounds, Pharmaceutical Composition and Methods for Use in Treating Inflammatory Diseases Formerly held In force Term ends Nov 27, 2034 · High confidence	In force	Term ends Nov 27, 2034	High confidence
US 11,731,974	N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Formerly held In force Term ends Jan 24, 2035 · From the USPTO record	In force	Term ends Jan 24, 2035	From the USPTO record
US 10,203,327	Organic Compounds Formerly held In force Term ends Feb 25, 2035 · High confidence	In force	Term ends Feb 25, 2035	High confidence

10 of 39 patents shown.

Pro members see all 39.

Pro members: see all 39 patents